Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 77

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 77
---
 in any other capacity for or on behalf of the Company) against any liability or expense actually
and reasonably incurred by such person in respect thereof. Note that for liabilities arising under the Securities Act, we have been advised
that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

<div align='center'>II-1</div>

Item 15. Recent Sales of Unregistered Securities.

Set forth below is information regarding securities
issued by us within the last three years which were not registered under the Securities Act of 1933, as amended.

| (a) | Issuance of Capital Stock. |

| ● | On July 11, 2023, we issued 1,049 shares of our common stock to Bigger Capital Fund, LP as a result of the conversion of the Convertible Promissory Note we issued to Bigger Capital Fund, LP on May 24, 2022 (the “Bigger Capital Fund Note”). |

| ● | On July 11, 2023, we issued 1,049 shares of our common stock to Sabby Volatility Warrant Master Fund, Ltd. as a result of the conversion of the Convertible Promissory Note we issued to Sabby Volatility Warrant Master Fund, Ltd. on May 8, 2023 (the “Sabby Note”). |

| ● | On July 14, 2023, we issued a total of 488 restricted shares of our common stock to BioIntelect Pty Ltd as deferred equity compensation valued in the amount of $155,000. |

| ● | On July 14, 2023, we converted the entirety of debt owed to a noteholder to 3,583 shares of our common stock at the conversion price equal to the initial public offering price, of which were issued to Xu Yu. |

| ● | On July 14, 2023, we issued 18,473 shares of common stock to Knight Therapeutics (Barbados) Inc.) (“Knight”) upon conversion of debt owed to Knight. |

| ● | On July 28, 2023, we issued 760 restricted shares of our common stock to Knight upon conversion of 2,162 shares of Series A Preferred Stock, at the conversion rate price detailed in Note 6 to the accompanying consolidated condensed financial statements. |

<div align='center'>II-2</div>

The issuances of shares of